Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

BACKGROUND: Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA <100,000 copies/mL. In resource-limited settings, pre-treatment HIV RNA is not routinely pe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:AIDS Res Ther
Autors principals: Kiertiburanakul, Sasisopin, Boettiger, David, Ng, Oon Tek, Van Kinh, Nguyen, Merati, Tuti Parwati, Avihingsanon, Anchalee, Wong, Wing-Wai, Lee, Man Po, Chaiwarith, Romanee, Kamarulzaman, Adeeba, Kantipong, Pacharee, Zhang, Fujie, Choi, Jun Yong, Kumarasamy, Nagalingeswaran, Ditangco, Rossana, Cuong, Do Duy, Oka, Shinichi, Sim, Benedict Lim Heng, Ratanasuwan, Winai, Ly, Penh Sun, Yunihastuti, Evy, Pujari, Sanjay, Ross, Jeremy L., Law, Matthew, Sungkanuparph, Somnuek
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5420083/
https://ncbi.nlm.nih.gov/pubmed/28484509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-017-0151-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars